地高辛治疗症状性风湿性心脏病:一项随机临床试验
该多中心随机安慰剂对照试验纳入1769例症状性风湿性心脏病患者,评估地高辛对全因死亡或新发/恶化心力衰竭复合终点的影响。
要点
- 地高辛降低症状性风湿性心脏病患者全因死亡或新发/恶化心衰复合终点风险。
- 地高辛组新发或恶化心衰发生率25.8%,低于安慰剂组的29.2%。
- 全因死亡两组无显著差异,地高辛毒性导致永久停药仅10例(1.1%)。
核心结论
- 在症状性风湿性心脏病患者中,地高辛降低了全因死亡或新发/恶化心力衰竭复合终点风险,且毒性风险低。
研究设计与样本
- 多中心、随机、安慰剂对照试验,在印度12家三级医院纳入1769例风湿性心脏病患者,按基线心律1:1随机分层。
- 地高辛组885例接受口服地高辛0.125-0.25 mg每日一次,安慰剂组884例接受匹配安慰剂。
- 1759例至少服用一剂研究药物者纳入主要分析,中位随访2.1年。
主要发现
- 新发或恶化心力衰竭在地高辛组发生227例(25.8%),安慰剂组257例(29.2%)(HR 0.82;95%CI 0.69-0.98)。
- 全因死亡在地高辛组88例(10%),安慰剂组91例(10.4%)(HR 0.94;95%CI 0.70-1.26)。
- 因地高辛毒性疑似永久停药:地高辛组10例(1.1%),安慰剂组1例。
关键数值与推荐
- 纳入标准:风湿性心脏病且合并心力衰竭或心房颤动或已在服用地高辛。
- 主要终点:36个月内全因死亡或新发/恶化心力衰竭复合终点。
- 地高辛剂量:口服0.125至0.25 mg每日一次。
临床怎么用
- 对于症状性风湿性心脏病合并心衰或房颤患者,地高辛可考虑用于降低死亡或心衰恶化复合风险。
- 使用地高辛时需监测毒性,但本试验中因疑似毒性永久停药率较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Heart failure is the most common cause of death in patients with rheumatic heart disease. The efficacy and safety of digoxin in this population are not known. OBJECTIVE: To determine if digoxin, compared with placebo, improves the composite of death or new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, placebo-controlled trial enrolling patients with rheumatic heart disease who additionally had heart failure or atrial fibrillation or were already taking digoxin at 12 tertiary care hospitals in India between February 25, 2022, and August 31, 2024; median follow-up was 2.1 years (until December 15, 2025). INTERVENTIONS: Patients were randomized in a 1:1 ratio, stratified by baseline rhythm, to receive oral digoxin, 0.125 to 0.25 mg once daily (n = 885), or matching placebo (n = 884). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause death or new-onset or worsening heart failure within 36 months of follow-up or until study end, whichever occurred first. Key secondary outcomes were all-cause death, new-onset or worsening heart failure, and a composite of heart failure-related death or new-onset or worsening heart failure. RESULTS: Of 1769 enrolled patients, 1759 took at least 1 dose of the study medication and were included in the primary analysis. The mean age was 46 years and 72% were female. Most patients (81.5%) had mixed lesions involving multiple valves, with 85% having moderate to severe mitral stenosis. Atrial fibrillation was present in 70%, and 90% were in New York Heart Association class II to IV. The primary composite outcome occurred in 276 patients (31.4%) receiving digoxin and 312 (35.5%) receiving placebo (hazard ratio, 0.82; 95% CI, 0.70-0.97; P = .02). New-onset or worsening heart failure occurred in 227 patients (25.8%) receiving digoxin and in 257 (29.2%) receiving placebo (hazard ratio, 0.82; 95% CI, 0.69-0.98). Most episodes of worsening heart failure were treated with augmentation of oral or intravenous diuretics without hospitalization. Death from any cause occurred in 88 patients (10%) receiving digoxin and 91 (10.4%) receiving placebo (hazard ratio, 0.94; 95% CI, 0.70-1.26). Ten patients receiving digoxin (1.1%) and 1 receiving placebo permanently discontinued study medication due to suspected digoxin toxicity. CONCLUSIONS AND RELEVANCE: In patients with symptomatic rheumatic heart disease, digoxin reduced the risk of a composite of all-cause death or new-onset or worsening heart failure, with little risk of toxicity. TRIAL REGISTRATION: CTRI Identifier: CTRI/2021/04/032858.
引用
- Karthikeyan G, Devasenapathy N, Ghosh A, et al. Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial. JAMA. 2026. PMID: 42106990. doi:10.1001/jama.2026.7335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。